Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression

Neoplasia

Volumn 10, Issue 8, 2008, Pages 847-856

  Wang, Jianghua ^a   Yu, Wendong ^a   Cai, Yi ^a   Ren, Chengxi ^a   Ittmann, Michael M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; DNA BINDING PROTEIN; FIBROBLAST GROWTH FACTOR 4; GLYCINE; PROTEIN HIP 1;

ARTICLE; CANCER GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA POLYMORPHISM; GENE EXPRESSION; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; MOLECULAR CLONING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 48249118837     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08450     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, and Thun MJ (2007). Cancer statistics, 2007. CA Cancer J Clin 57, 43-66.
2. Kwabi-Addo B, Ozen M, and Ittmann M (2004). The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 11, 709-724.
3. Powers CJ, McLeskey SW, and Wellstein A (2000). Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 7, 165-197.
4. Ozen M, Giri D, Ropiquet F, Mansukhani A, and Ittmann M (2001). Role of fibroblast growth factor receptor signaling in prostate cancer cell survival. J Natl Cancer Inst 93, 1783-1790.
5. Reiland J, Kempf D, Roy M, Denkins Y, and Marchetti D (2006). FGF2 binding, signaling, and angiogenesis are modulated by heparanase in metastatic melanoma cells. Neoplasia 8, 596-606.
6. Dorkin TJ, Robinson MC, Marsh C, Neal DE, and Leung HY (1999). aFGF immunoreactivity in prostate cancer and its co-localization with bFGF and FGF8. J Pathol 189, 564-569.
7. Giri D, Ropiquet F, and Ittmann M (1999). Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 5, 1063-1071.
8. Gravdal K, Halvorsen OJ, Haukaas SA, and Akslen LA (2006). Expression of bFGF/FGFR-1 and vascular proliferation related to clinicopathologic features and tumor progress in localized prostate cancer. Virchows Arch 448, 68-74.
9. Ropiquet F, Giri D, Kwabi-Addo B, Mansukhani A, and Ittmann M (2000). Increased expression of fibroblast growth factor 6 in human prostatic intraepithelial neoplasia and prostate cancer. Cancer Res 60, 4245-4250.
10. Dorkin TJ, Robinson MC, Marsh C, Bjartell A, Neal DE, and Leung HY (1999). FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene 18, 2755-2761.
11. West AF, O'Donnell M, Charlton RG, Neal DE, and Leung HY (2001). Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer. Br J Cancer 85, 576-583.
12. Heer R, Douglas D, Mathers ME, Robson CN, and Leung HY (2004). Fibroblast growth factor 17 is over-expressed in human prostate cancer. J Pathol 204, 578-586.
13. Eswarakumar VP, Lax I, and Schlessinger J (2005). Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16, 139-149.
14. Martin-Orozco RM, Almaraz-Pro C, Rodriguez-Ubreva FJ, Cortes MA, Ropero S, Colomer R, Lopez-Ruiz P, and Colas B (2007). EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt. Neoplasia 9, 614-624.
15. 388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res 10, 6169-6178.
16. Gowardhan B, Douglas DA, Mathers ME, McKie AB, McCracken SR, Robson CN, and Leung HY (2005). Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer 92, 320-327.
17. Sahadevan K, Darby S, Leung H, Mathers M, Robson C, and Gnanapragasam V (2007). Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol 213, 82-90.
18. Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M, Knyazeva T, Muller S, Gartner S, Sures I, et al. (2002). Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 62, 840-847.
19. Morimoto Y, Ozaki T, Ouchida M, Umehara N, Ohata N, Yoshida A, Shimizu K, and Inoue H (2003). Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer 98, 2245-2250.
20. 388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients. Br J Cancer 94, 1879-1886.
21. 388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol 23, 7307-7311.
22. 388 allele in head and neck squamous cell carcinoma. Int J Cancer 111, 213-217.
23. 388 allele correlates with survival in head and neck squamous cell carcinoma. Exp Mol Pathol 82, 53-57.
24. Jezequel P, Campion L, Joalland MP, Millour M, Dravet F, Classe JM, Delecroix V, Deporte R, Fumoleau P, and Ricolleau G (2004). G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis. Br J Cancer 90, 189-193.
25. 388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 24, 3747-3755.
26. Wang J, Cai Y, Penland R, Chauhan S, Miesfeld RL, and Ittmann M (2006). Increased expression of the metastasis-associated gene Ehm2 in prostate cancer. Prostate 66, 1641-1652.
27. Monsonego-Ornan E, Adar R, Feferman T, Segev O, and Yayon A (2000). The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation. Mol Cell Biol 20, 516-522.
28. Cho JY, Guo C, Torello M, Lunstrum GP, Iwata T, Deng C, and Horton WA (2004). Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia. Proc Natl Acad Sci USA 101, 609-614.
29. Hyun TS, Rao DS, Saint-Dic D, Michael LE, Kumar PD, Bradley SV, Mizukami IF, Oravecz-Wilson KI, and Ross TS (2004). HIP1 and HIP1r stabilize receptor tyrosine kinases and bind 3-phosphoinositides via epsin N-terminal homology domains. J Biol Chem 279, 14294-14306.
30. Rao DS, Bradley SV, Kumar PD, Hyun TS, Saint-Dic D, Oravecz-Wilson K, Kleer CG, and Ross TS (2003). Altered receptor trafficking in Huntingtin interacting protein 1-transformed cells. Cancer Cell 3, 471-482.
31. Rao DS, Hyun TS, Kumar PD, Mizukami IF, Rubin MA, Lucas PC, Sanda MG, and Ross TS (2002). Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival. J Clin Invest 110, 351-360.
32. Wang J, Cai Y, Ren C, and Ittmann M (2006). Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 66, 8347-8351.
33. Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G, and Goldfarb M (1996). Receptor specificity of the fibroblast growth factor family. J Biol Chem 271, 15292-15297.
34. Mohammadi M, Dikic I, Sorokin A, Burgess WH, Jaye M, and Schlessinger J (1996). Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. Mol Cell Biol 16, 977-989.
35. Bradley SV, Holland EC, Liu GY, Thomas D, Hyun TS, and Ross TS (2007). Huntingtin interacting protein 1 is a novel brain tumor marker that associates with epidermal growth factor receptor. Cancer Res 67, 3609-3615.
36. Ross TS and Gilliland DG (1999). Transforming properties of the Huntingtin interacting protein 1/platelet-derived growth factor beta receptor fusion protein. J Biol Chem 274, 22328-22336.
37. Watson GA, Zhang X, Stang MT, Levy RM, Queiroz de Oliveira PE, Gooding WE, Christensen JG, and Hughes SJ (2006). Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma. Neoplasia 8, 949-955.